News

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.
The intense demand for GLP-1 agonists stems from their proven efficacy in managing type 2 diabetes and, increasingly, in facilitating significant weight loss. However, patients often face substantial ...
In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
The DOJ has charged 324 individuals in a $14.6B healthcare fraud case—the largest in US history—exposing billing scams, ...
Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives’ time to shine GLP-1 drugs first came onto the market to treat type 2 ...
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...
Patients taking semaglutide, the active ingredient in Ozempic, were less likely to develop Alzheimer’s. Randomized clinical trials are needed to pin down the exact cause of this difference in risk.
Interpol cited a concerning rise in demand for unauthorised weight loss drugs and peptide supplements in Europe and other wealthy regions.
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.